TAM
EPIX

Tucker Asset Management’s ESSA Pharma EPIX Stock Holding History

Tucker Asset Management’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,097
Closed -$137K – 1712
2024
Q1 		$137K Buy
+16,097
New +$141K 0.03% 219

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Tucker Asset Management's EPIX Position: Q2 2024 in Review

Tucker Asset Management sold out of ESSA Pharma (EPIX) in Q2 2024, closing a stake of 16,097 shares — an estimated $137K sold.

Tucker Asset Management first reported a position in EPIX in Q1 2024 and held it in 1 quarter. The position peaked at $137K in Q1 2024. 31 funds tracked by Wall St. Rank hold EPIX as of Q2 2024.

  • Tucker Asset Management reported no remaining ESSA Pharma position as of Q2 2024 after selling out during the quarter.
  • Tucker Asset Management sold 16,097 ESSA Pharma shares in Q2 2024, an estimated $137K.
  • Tucker Asset Management first reported a position in ESSA Pharma in Q1 2024 and held it in 1 quarter.
  • Tucker Asset Management's ESSA Pharma position peaked at $137K in Q1 2024.
  • 31 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2024.

Based on Tucker Asset Management's 13F filing for Q2 2024, filed 9 Aug 2024.